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Abstract 
Background: Multiple red blood cell (RBC) variants appear to offer protection against the most severe forms of Plas-
modium falciparum malaria. Associations between these variants and uncomplicated malaria are less clear.
Methods: Data from a longitudinal cohort study conducted in 3 sub‑counties in Uganda was used to quantify asso‑
ciations between three red blood cell variants Hb [AA, AS, S (rs334)], alpha thalassaemia 3.7 kb deletion, and glucose‑
6‑phosphate dehydrogenase deficiency A—(G6PD 202A genotype) and malaria incidence, parasite prevalence, 
parasite density (a measure of anti‑parasite immunity) and body temperature adjusted for parasite density (a measure 
of anti‑disease immunity). All analyses were adjusted for age, average household entomological inoculation rate, and 
study site. Results for all variants were compared to those for wild type genotypes.
Results: In children, HbAS was associated, compared to wild type, with a lower incidence of malaria (IRR = 0.78, 
95% CI 0.66–0.92, p = 0.003), lower parasite density upon infection (PR = 0.66, 95% CI 0.51–0.85, p = 0.001), and lower 
body temperature for any given parasite density (− 0.13 ℃, 95% CI − 0.21, − 0.05, p = 0.002). In children, HbSS was 
associated with a lower incidence of malaria (IRR = 0.17, 95% CI 0.04–0.71, p = 0.02) and lower parasite density upon 
infection (PR = 0.31, 95% CI 0.18–0.54, p < 0.001). α−/αα thalassaemia, was associated with higher parasite prevalence 
in both children and adults (RR = 1.23, 95% CI 1.06–1.43, p = 0.008 and RR = 1.52, 95% CI 1.04–2.23, p = 0.03, respec‑
tively). G6PD deficiency was associated with lower body temperature for any given parasite density only among male 
hemizygote children (− 0.19 ℃, 95% CI − 0.31, − 0.06, p = 0.003).
Conclusion: RBC variants were associated with non‑severe malaria outcomes. Elucidation of the mechanisms by 
which they confer protection will improve understanding of genetic protection against malaria.
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Background
Multiple red blood cell (RBC) variants are associated 
with protection against severe Plasmodium falciparum 
malaria. Studies conducted in numerous populations 
have consistently shown that people with HbAS have a 
70–90% reduced risk of severe malaria [1–4]. Similarly, 
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both α−/αα and α−/α− thalassaemia reduce the risk 
of severe malaria by 20–40% [5–7]. The association 
between glucose-6-phosphate dehydrogenase [G6PD] 
deficiency and severe malaria is less clear [4, 8]. Some 
studies reported that G6PD protects both heterozygous 
females and hemizygous males from severe malaria [9], 
others reported protection for only hemizygous males 
[10], and others reported no protection [8]. Mechanisms 
through which these variants confer protection appear to 
be complex and may include restriction of red blood cell 
invasion and intracellular growth, increased destruction 
of parasitized red cells, and improved cell mediated and 
humoral immune responses [11–17].
While protective associations between certain RBC 
variants and severe malaria have been shown consist-
ently [7, 18], associations with uncomplicated malaria 
have been less straightforward. Multiple studies showed 
reduced risk of malaria [19–24] and lower parasite den-
sities [4, 25, 26] with HbAS compared to wild-type. For 
alpha thalassaemia, studies suggested both protection 
against and enhancement of malaria [5, 6, 27, 28]. For 
G6PD deficiency, studies in Africa [29–32], but not Asia 
[8, 33–35] suggested protection against uncomplicated 
malaria. Some discrepancies in findings might be attrib-
uted to differences between studies in human popula-
tions, transmission settings, and study designs.
Data from three cohorts conducted in areas of low, 
moderate, and high malaria transmission intensity in 
Uganda was used to quantify associations between three 
red blood cell variants and uncomplicated malaria out-
comes. Notably, the cohort studies included passive sur-
veillance for symptomatic malaria, active surveillance for 
P. falciparum infection, and regular entomological sur-
veys to quantify transmission risk.
Methods
Study design, sites, and population
Prospective cohort studies were conducted at three 
sites. Study sites were Walukuba, Jinja District, a peri 
urban area in South Central Uganda with a low malaria 
transmission intensity (annual entomological inocula-
tion rate (aEIR) or number of infective mosquito bites 
per person per year = 2.8); Kihihi, Kanungu District, 
a predominantly rural area in south western Uganda 
with moderate malaria transmission (aEIR = 32); and 
Nagongera, Tororo District, a predominantly rural area 
in south eastern Uganda with a very high transmission 
intensity (aEIR = 310) [36] until initiation of indoor resid-
ual spraying of insecticide in late 2014 [37]. Details on 
how the study households and participants were selected 
has been described elsewhere [36]. Briefly, in each of the 
3 sub-counties 100 households were randomly enrolled. 
Households were included if they had at least one child 
between 6  months and 10  years of age and at least one 
adult resident providing informed consent. All children 
and one adult primary care giver from each household 
meeting the eligibility criteria were invited to participate. 
Participants were followed-up until they reached 11 years 
of age or until they were withdrawn from the study either 
voluntarily or because they failed to comply with study 
visits.
Study procedures and follow‑up
Study procedures and follow up have been described 
in detail [36–38]. Briefly, all participants were given an 
insecticide treated bed net at enrollment and were fol-
lowed for all their healthcare needs at dedicated study 
clinics open 7 days each week. Participants were provided 
free health care and clinic travel expenses, but received 
no other incentives to participate. Episodes of malaria 
were diagnosed by passive case detection and defined 
as a history of fever within the past 24 h or an elevated 
temperature (≥ 38.0 ℃ tympanic) with a positive malaria 
thick blood smear. Episodes of malaria were treated with 
artemether-lumefantrine (uncomplicated malaria) or 
intravenous quinine or artesunate (complicated malaria), 
following national guidelines at the time of the studies. In 
addition, participants were asked to make a routine visit 
to the study clinic every 3 months. At each of these vis-
its, a thick blood smear was evaluated to assess for para-
sitaemia. The cohorts were dynamic, such that all newly 
eligible children were enrolled, and participants were 
withdrawn when they reached 11 years of age.
Household level EIR was estimated using data from 
entomologic surveys carried out concurrently with the 
cohort studies, as previously described [39]. Briefly, one 
CDC light trap collection was carried out monthly in the 
main sleeping room of each house. The average house-
hold EIR was calculated as the average number of female 
Anopheles mosquitoes collected per night multiplied by 
the proportion of mosquitoes containing sporozoites at 
each site.
Laboratory methods
Presence of three RBC variants, the sickle locus (rs334), 
− 3.7α− thalassemia and G6PD-G202A (rs1050828), was 
tested as previously described [40]. Briefly, genes of inter-
est were amplified, amplicons subjected to mutation-
specific restriction endonuclease digestion (for sickle 
haemoglobin and G6PD deficiency), reaction products 
resolved by electrophoresis, and genotypes determined 
based on the sizes of reaction products. For assessment 
of parasitaemia, thick blood smears were stained with 2% 
Giemsa, allowed to dry for 30  min, and read by experi-
enced laboratory technologists. Parasite densities were 
calculated by counting the number of asexual parasites 
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per 200 leukocytes or per 500 leukocytes if the count was 
less than 10 asexual parasites per 200 leukocytes, assum-
ing a leukocyte count of 8000 per microlitre [41]. A blood 
smear was considered negative if the examination of 100 
high power fields did not reveal any asexual parasites. 
For quality control, blood smears were read by a sec-
ond microscopist, and discrepancies resolved by a third 
microscopist.
Statistical methods
All data were collected using standardized forms and 
subsequently entered into Microsoft access before trans-
fer to STATA (Version 14; STATA Corp., College Sta-
tion, TX, USA) and R for analyses [42]. The data analysed 
were for participants enrolled from August 2011 through 
December 2014 and followed through June 2016. Study 
participants were included in the analyses if they had 
results for at least one RBC variant tested and at least 
2 months of follow-up. Associations between RBC vari-
ants and malaria incidence were quantified using negative 
binomial regression models with measures of association 
expressed as the incidence rate ratio (IRR). Associations 
between RBC variants and parasite prevalence at the time 
of each routine visit were quantified using log-binomial 
generalized estimating equations with robust standard 
errors to generate prevalence ratios (PR). Effects of RBC 
variants on two components of anti-malarial immunity, 
anti-parasite immunity (ability to control parasite den-
sities upon infection) and anti-disease immunity (ability 
to tolerate higher parasite density without developing 
fever) were also investigated. To model these outcomes, 
generalized additive models (GAMS) were used as previ-
ously described [38]. The outcome of interest in the anti-
parasite immunity model was the log10 parasite density 
in parasite positive visits, and the outcome of interest in 
the anti-disease model was the measured temperature, 
adjusted for parasite density. All analyses were adjusted 
for age, average household level EIR, and study site, and 
included random effects at the individual and house-
hold level to account for clustering. For each RBC vari-
ant, the group with wild type genotype was chosen as the 
reference.
1044 parcipants enrolled from August 5th to October 1st 2011
300 new enrollees during dynamic recruitment 
1344 total parcipants enrolled
12 with no results for red cell variants
1322 parcipants included in the analyses
1010 children 0.5 to 10 years of age
312 adults 18 years or older
540 withdrawn from the study
218 reached 11 years of age
191 moved out of study area
64 lost to follow-up
28 unable to comply with study protocol
22 withdrawal of all children under their care
12 withdrawal of informed consent
5 died 
782 completed follow-up through June 30th 2016
567 children 0.5 to 10 years of age
215 adults 18 years or older
10 with less than 2 months of follow-up 
Fig. 1 Flow diagram of participants included in the analyses
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Results
Characteristics of participants in the study
Of 1344 participants enrolled in the cohort studies, 1322 
(98.4%) were included in the analyses and 782 of these 
(59.2%) were followed through the end of June 2016 
(Fig. 1). A total of 1010 (76.4%) participants were children 
0.5–10 years of age and 312 (23.6%) were adult primary 
care givers. Approximately half the children and 94% of 
adults were female (Table  1). Overall, the prevalence of 
all 3 red blood cell variants, Hb variant, alpha thalassae-
mia, and G6PD deficiency were highly variable across the 
three sites with Nagongera having the highest prevalence 
and Kihihi the lowest (Additional file 1: Table S1).
Associations between RBC variants and malaria incidence
The overall incidence of malaria across the 3 sites was 
1.60 episodes per person year (PPY) among children and 
0.31 episodes PPY among adults. Among children, HbAS 
was associated with a 22% lower incidence of malaria 
(IRR = 0.78, 95% CI 0.66–0.92, p = 0.003) and HbSS with 
an 83% lower incidence of malaria (IRR = 0.17, 95% CI 
0.04–0.71, p = 0.02), compared to children with wild type 
genotypes (Table 2). In contrast, among adults there was 
no association between HbAS and malaria incidence 
(IRR = 0.99, 95% CI 0.66–1.49, p = 0.98). For both chil-
dren and adults there were no significant associations 
between alpha thalassaemia or G6PD deficiency and 
malaria incidence (Table 2).
Associations between RBC variants and prevalence 
of microscopic parasitaemia
The prevalence of microscopic parasitaemia at the time of 
routine visits across the 3 sites was 15.8% among children 
and 4.5% among adults. There were no significant asso-
ciations between HbAS and parasite prevalence among 
children or adults. Children with HbSS had a 69% lower 
prevalence of parasitaemia compared to those with wild 
type genotype (PR = 0.31, 95% CI 0.18–0.54, p < 0.001) 
(Table 3). For both children and adults, α−/αα thalassae-
mia, but not α−/α− thalassaemia, was associated with a 
higher parasite prevalence compared to that in wild type 
individuals (RR = 1.23 95% CI 1.06–1.43, p = 0.008 and 
RR = 1.52, 95% CI 1.04–2.23, p = 0.03, respectively). For 
children and adults there were no significant associations 
between G6PD deficiency and microscopic parasitaemia 
(Table 3).
Associations between RBC variants and parasite densities 
upon infection (anti‑parasite immunity) in children
Among children who were parasitaemic, the overall geo-
metric mean parasite density was 11,400 parasites per µL 
(95% CI 10,800–12,100). On average, children with HbAS 
had lower parasite densities by a factor of 0.66 (95% CI 
0.51–0.85, p = 0.001) compared to children with wild 
type genotype. There were no significant associations 
between alpha thalassaemia or G6PD deficiency and par-
asite densities (Table 4).
Associations between RBC variants and body temperature 
upon infection (anti‑disease immunity) in children
Among children who were parasitaemic, the mean tym-
panic temperature was 37.6 °C (IQR 37.6–37.7). In mod-
els adjusted for parasite density, parasitaemic children 
with HbAS had body temperatures that were on average 
0.13 °C lower (95% CI, 0.05–0.21, p = 0.002) at the time of 
the visit, compared to children with wild type genotype. 
There were no significant associations between alpha 
thalassaemia and body temperature among parasitaemic 
children. Upon stratification, parasitaemic male children 
that were G6PD hemizygotes had temperatures that were 
0.19  °C lower (95% CI 0.06–0.31, p = 0.003) compared 
those with the wild type G6PD genotype. There were 
no significant associations between G6PD deficiency 
Table 1 Baseline characteristics of  participants included 
in the analyses
a Proportion among those with results available
Characteristic Children, n (%)a Adults, n (%)a
Study site
 Walukuba 318 (31.5%) 113 (36.2%)
 Kihihi 357 (35.4%) 95 (30.5%)
 Nagongera 335 (33.2%) 104 (33.3%)
Gender
 Male 516 (51.1%) 19 (6.1%)
 Female 494 (48.9%) 293 (93.9%)
Haemoglobin variant
 AA 808 (80.7%) 242 (78.3%)
 AS 188 (18.8%) 67 (21.7%)
 SS 5 (0.5%) 0 (0%)
 No result 9 3
Alpha thalassaemia variant
 Normal 585 (60.3%) 200 (66.0%)
 α−/αα 335 (34.5%) 84 (27.7%)
 α−/−α 50 (5.2%) 19 (6.3%)
 No result 40 9
G6PD genotype (male)
 Normal 455 (89.4%) 15 (79.0)
 Hemizygotes 54 (10.6%) 4 (21.1%)
 No result 7 0
G6PD genotype (female)
 Normal 370 (75.5%) 232 (79.5%)
 Heterozygotes 108 (22.0%) 55 (18.8%)
 Homozygotes 12 (2.4%) 5 (1.7%)
 No result 4 1
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and temperature among female parasitaemic children 
(Table 5).
Discussion
This study used data from 1322 participants enrolled in 
three longitudinal cohorts in Uganda to investigate asso-
ciations between RBC variants and several outcomes 
of uncomplicated P. falciparum infection. Compared 
to children with wild type haemoglobin, children with 
HbAS had a reduced risk of incident malaria, developed 
lower parasite densities upon infection, and tolerated 
higher parasite densities without developing fever. Asso-
ciations with other RBC variants were less straightfor-
ward: α−/αα thalassaemia was associated with higher 
parasite prevalence in both children and adults; G6PD 
deficient male hemizygote children, but not females, tol-
erated higher parasite densities without developing fever. 
These findings are consistent with recent findings from 
Uganda and elsewhere showing that HbAS is associated 
with protection in children, but not adults, from symp-
tomatic malaria [2, 7, 19] and is also associated with low 
parasite densities during symptomatic disease [4, 19, 43]. 
Children with HbSS were also strongly protected against 
incident malaria. Furthermore, HbSS children were also 
less likely to develop high temperatures for any given 
parasite density, as compared to children with wild type 
haemoglobin (i.e.; they had higher anti-disease immu-
nity). The mechanisms by which HbAS protects the 
host against symptomatic and severe disease have been 
extensively explored and appear to be complex. Some of 
the proposed mechanisms include increased sickling of 
parasitized RBCs, enhanced phagocytosis of parasitized 
RBCs, reduced intraerythrocytic parasite growth, and 
decreased cytoadherence via reduced expression of P. 
falciparum Erythrocyte Membrane Protein 1 (PfEMP-
1) [11, 44]. The lack of protection associated with HbAS 
in adults is likely due to the predominant role played by 
acquired immunity among older age groups in highly 
endemic regions.
In contrast to results for HbS, there were no protec-
tive associations between alpha thalassaemia and any of 
the outcomes measured. In fact, although α−/αα tha-
lassaemia has been associated with protection against 
both severe [5, 6, 18, 22] and uncomplicated forms of 
malaria [27, 28] in this study of uncomplicated malaria 
it was associated with a higher parasite prevalence in 
both children and adults as compared to the wild type. 
Similar associations have been previously suggested [45]. 
Table 2 Associations between RBC variants and malaria incidence
* Adjusted for age, average household EIR, and study site
Age group Red cell variants Variant Malaria 
episodes
Person years 
of follow‑up
Incidence 
of malaria 
PPY
Unadjusted Adjusted*
IRR (95% CI) p‑value IRR (95% CI) p‑value
Children Haemoglobin variant AA 4612 2762 1.67 Reference Reference
AS 818 620 1.32 0.77 (0.64–0.94) 0.009 0.78 (0.66–0.92) 0.003
SS 3 13.4 0.22 0.16 (0.03–0.78) 0.02 0.17 (0.04–0.71) 0.02
Alpha thalassaemia 
variant
Normal 3233 2061 1.57 Reference Reference
α−/αα 1769 1106 1.60 1.00 (0.85–1.18) 0.98 1.04 (0.91–1.20) 0.56
α−/−α 251 150 1.67 0.97 (0.68–1.38) 0.88 1.19 (0.87–1.62) 0.27
G6PD genotype Normal (male) 2680 1597 1.68 Reference Reference
Hemizygotes 374 170 2.20 1.18 (0.85–1.63) 0.33 0.93 (0.71–1.22) 0.61
Normal (female) 1768 1224 1.44 Reference Reference
Heterozygotes 484 355 1.36 0.91 (0.70–1.18) 0.46 0.80 (0.63–1.01) 0.06
Homozygotes 72 40.5 1.78 1.21 (0.60–2.44) 0.59 0.89 (0.51–1.57) 0.70
Adults Haemoglobin variant AA 300 936 0.32 Reference Reference
AS 69 252 0.27 0.85 (0.56–1.30) 0.46 0.99 (0.66–1.49) 0.98
Alpha thalassaemia 
variant
Normal 252 783 0.32 Reference Reference
α−/αα 102 318 0.32 1.01 (0.68–1.48) 0.98 1.10 (0.76–1.59) 0.63
α−/−α 11 70.0 0.16 0.50 (0.22–1.15) 0.10 0.58 (0.25–1.33) 0.20
G6PD genotype Normal (male) 13 55.1 0.23 Reference Reference
Hemizygotes 3 19.4 0.16 0.66 (0.15–2.90) 0.58 0.98 (0.16–5.85) 0.98
Normal (female) 294 995 0.30 Reference Reference
Heterozygotes 73 191 0.38 1.26 (0.81–1.97) 0.31 1.13 (0.74–1.72) 0.58
Homozygotes 1 11.2 0.09 0.39 (0.03–4.41) 0.45 0.40 (0.04–3.92) 0.43
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However, α−/αα thalassaemia did not have any associa-
tion with incidence of symptomatic disease, parasite den-
sities or anti-disease immunity.
Interestingly, the results from this study suggest 
that G6PD deficiency may play a role in anti-disease 
immunity. For any given parasite density, G6PD hemizy-
gous parasitaemic male children had lower temperatures 
than wild type parasitaemic male children upon P. falci-
parum infection. Thus, G6PD deficiency may be asso-
ciated with increased ability to tolerate high parasite 
Table 3 Associations between RBC variants and prevalence of microscopic parasitaemia at the time of each routine visit
* Adjusted for age, average household EIR, and study site
Age group Red cell variants Variant Parasite prevalence Unadjusted Adjusted*
PR (95% CI) p‑value PR (95% CI) p‑value
Children Haemoglobin variant AA 2488/15,830 (15.7%) Reference Reference
AS 597/3636 (16.4%) 1.07 (0.89–1.30) 0.46 0.95 (0.80–1.13) 0.57
SS 3/66 (4.6%) 0.31 (0.14–0.68) 0.004 0.31 (0.18–0.54) <0.001
Alpha thalassaemia variant Normal 1621/11,664 (13.9%) Reference Reference
alpha+ (α−/αα) 1272/6397 (19.9%) 1.45 (1.24–1.70) <0.001 1.23 (1.06–1.43) 0.008
alpha0 (α−/−α) 127/937 (13.6%) 0.96 (0.66–1.40) 0.83 0.98 (0.66–1.44) 0.91
G6PD genotype Normal (male) 1593/9147 (17.4%) Reference Reference
Hemizygotes 194/1030 (18.8%) 1.09 (0.81–1.48) 0.57 0.86 (0.65–1.14) 0.30
Normal (female) 887/7039 (12.6%) Reference Reference
Heterozygotes 372/2062 (18.0%) 1.35 (1.04–1.75) 0.02 1.13 (0.87–1.45) 0.36
Homozygotes 46/243 (18.9%) 1.38 (0.75–2.54) 0.30 0.92 (0.53–1.59) 0.76
Adults Haemoglobin variant AA 187/3952 (4.7%) Reference Reference
AS 37/1050 (3.5%) 0.72 (0.45–1.15) 0.17 0.74 (0.45–1.22) 0.24
Alpha thalassaemia variant Normal 128/3307 (3.9%) Reference Reference
alpha+ (α−/αα) 81/1332 (6.1%) 1.59 (1.08–2.34) 0.02 1.52 (1.04–2.23) 0.03
α−/−α 15/290 (5.2%) 1.35 (0.76–2.42) 0.30 1.16 (0.63–2.14) 0.64
G6PD genotype Normal (male) 8/229 (3.5%) reference reference
Hemizygotes 7/79 (8.9%) 2.48 (0.72–8.52) 0.15 5.10 (0.58–44.9) 0.14
Normal (female) 173/3792 (4.6%) Reference Reference
Heterozygotes 37/880 (4.2%) 0.87 (0.58–1.31) 0.51 0.77 (0.52–1.15) 0.20
Homozygotes 3/50 (6.0%) 1.38 (0.42–4.50) 0.59 1.34 (0.44–4.05) 0.61
Table 4 Associations between red cell variants and parasite densities (anti-parasite immunity) in parasitaemic children
* Adjusted for age, average household EIR, and study site
Red cell variants Variant Unadjusted Adjusted*
Change in  log10 parasite 
density (95% CI)
p‑value Change in  log10 parasite 
density (95% CI)
p‑value
Haemoglobin variant AA Reference Reference
AS − 0.25 (− 0.37, − 0.12) < 0.001 − 0.18 (− 0.29, − 0.07) 0.001
SS − 0.4 (− 1.33, 0.53) 0.40 − 0.11 (− 0.95, 0.73) 0.80
Alpha thalassaemia variant Normal Reference Reference
α−/αα − 0.20 (− 0.30, − 0.10) < 0.001 − 0.06 (− 0.14, 0.03) 0.19
α−/−α 0.09 (− 0.14, 0.31) 0.45 0.04 (− 0.15, 0.22) 0.71
G6PD genotype Normal (male) Reference Reference
Hemizygotes − 0.01 (− 0.22, 0.20) 0.92 − 0.01 (− 0.18, 0.17) 0.94
Normal (female) Reference Reference
Heterozygotes − 0.18 (− 0.34, − 0.01) 0.04 − 0.05 (− 0.19, 0.09) 0.51
Homozygotes 0.05 (− 0.34, 0.44) 0.80 0.12 (− 0.21, 0.45) 0.46
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densities without developing fever. However, the protec-
tive effect against symptomatic malaria was seen only in 
males, and not in heterozygous or homozygous females. 
There is considerable evidence to suggest that G6PD 
protects both male [10] and female [30, 46, 47] African 
children against severe malaria. However, information 
regarding G6PD protection from uncomplicated malaria 
is less clear albeit with a leaning towards protection for 
female children [4, 8, 24].
Results for associations between G6PD deficiency and 
uncomplicated malaria remain inconclusive.
This study had several limitations. First, sample sizes 
were small for certain groups, notably the SS and G6PD 
homozygous genotypes, which limited the ability to 
evaluate their associations with malaria outcomes. How-
ever, these genotypes occurred at expected frequencies 
in these populations and sample sizes would be prohibi-
tively large to study them in a cohort. Second, parasitae-
mia was measured using microscopy, which is much less 
sensitive than molecular techniques for identifying para-
sites [48–50]. Impacts of RBC variants on sub-micro-
scopic parasitaemia were not studied. Third, the degree 
of fever measured during symptomatic malaria may have 
been influenced by children receiving antipyretics prior 
to evaluation in the clinic. However, the majority of the 
patients presented to the study clinics within 24–48  h 
of symptom onset. Moreover, participants were encour-
aged to present to the clinic for all their health care needs 
as soon as they were unwell. Fourth, the study did not 
explore associations between red blood cell variants and 
other measures of protective immunity such as P. falci-
parum antibodies. Finally, there were very few cases of 
severe malaria, precluding exploration of associations 
between host polymorphisms and severe malaria.
Conclusion
In areas endemic for falciparum malaria, RBC vari-
ants may play an important role in protecting children 
against malaria. First, both HbAS and alpha thalassae-
mia are associated with decreased incidence of severe 
malaria. These strong associations probably explain 
the persistence of these balanced polymorphisms in 
human populations at risk of falciparum malaria. Sec-
ond, some polymorphisms also appear to protect 
against uncomplicated malaria. Identified associations 
with HbAS provide the strongest evidence of protec-
tion, with evidence for lower risks of malarial incidence 
and enhancement of both anti-parasite and anti-disease 
immunity. G6PD deficiency may provide additional 
protection against progression to symptomatic dis-
ease, with evidence for enhanced anti-disease immu-
nity. While the mechanisms by which common RBC 
variants protect against malaria remain incompletely 
understood, their associations with protection against 
malaria underline the exceptional selective pressure of 
malaria on the human genome.
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Table 5 Associations between  RBC variants and  temperature adjusted for  parasite density (anti-disease immunity) 
in parasitaemic children
* Adjusted for parasite density, age, average household EIR, and study site
Red cell variants Variant Unadjusted Adjusted*
Change in temperature 
in  °C (95% CI)
p‑value Change in temperature 
in  °C (95% CI)
p‑value
Haemoglobin variant AA Reference Reference
AS − 0.13 (− 0.22, − 0.04) 0.003 − 0.13 (− 0.21, − 0.05) 0.002
SS 0.09 (− 0.68, 0.86) 0.82 0.22 (− 0.52, 0.96) 0.56
Alpha thalassaemia variant Normal Reference Reference
α−/αα − 0.10 (− 0.17, − 0.03) 0.003 − 0.09 (− 0.21, 0.02) 0.11
α−/−α − 0.08 (− 0.24, 0.08) 0.31 − 0.16 (− 0.41, 0.08) 0.20
G6PD genotype Normal (male) Reference Reference
Hemizygotes − 0.12 (− 0.25, 0.01) 0.07 − 0.19 (− 0.31, − 0.06) 0.003
Normal (female) Reference Reference
Heterozygotes − 0.12 (− 0.24, 0.01) 0.07 − 0.09 (− 0.21, 0.02) 0.11
Homozygotes − 0.08 (− 0.37, 0.20) 0.57 − 0.16 (− 0.41, 0.08) 0.20
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